Abstract
The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology.
Keywords: Protein tyrosine phosphatase, p27, CDK2, cyclin D, SH2 domain, cancer, PTPN6, PTKs, pRb, TCR, cGMP
Anti-Cancer Agents in Medicinal Chemistry
Title: SHP-1 in Cell-Cycle Regulation
Volume: 11 Issue: 1
Author(s): Pilar Lopez-Ruiz, Javier Rodriguez-Ubreva, Ariel Ernesto Cariaga, Maria Alicia Cortes and Begona Colas
Affiliation:
Keywords: Protein tyrosine phosphatase, p27, CDK2, cyclin D, SH2 domain, cancer, PTPN6, PTKs, pRb, TCR, cGMP
Abstract: The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology.
Export Options
About this article
Cite this article as:
Lopez-Ruiz Pilar, Rodriguez-Ubreva Javier, Ernesto Cariaga Ariel, Alicia Cortes Maria and Colas Begona, SHP-1 in Cell-Cycle Regulation, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941154
DOI https://dx.doi.org/10.2174/187152011794941154 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diagnostic Usage of Low Dose CT in Solitary Pulmonary Nodule Follow Up in Daily Practice
Current Medical Imaging Unveiling the Transient Protein-Protein Interactions that Regulate the Activity of Human Lemur Tyrosine Kinase-3 (LMTK3) Domain by Cyclin Dependent Kinase 5 (CDK5) in Breast Cancer: An in silico Study
Current Proteomics Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles
Anti-Cancer Agents in Medicinal Chemistry Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Current Molecular Medicine The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Metabolic Targets of Cardiac HormonesTherapeutic Anti-Cancer Effects
Current Pharmaceutical Design Improvements in Algorithms for Phenotype Inference: The NAT2 Example
Current Drug Metabolism The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Chemotherapy-Induced Peripheral Neuropathic Pain and Rodent Models
CNS & Neurological Disorders - Drug Targets Elucidation of Cellular Metabolism Via Metabolomics and Stable-Isotope Assisted Metabolomics
Current Pharmaceutical Biotechnology Role of CHK2 Inhibitors in the Cellular Responses to Ionizing Radiation
Mini-Reviews in Medicinal Chemistry Editorial from Editor-in-Chief. Postoperative Pulmonary Complications and the Importance of the Preoperative Evaluation
Current Respiratory Medicine Reviews Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Editorial [Hot Topic: Tyrosine Kinase Inhibitors in Cancer Therapy (Guest Editor: S. Eckhardt)]
Anti-Cancer Agents in Medicinal Chemistry Preface
Current Topics in Medicinal Chemistry 4-Methylumbelliferones Analogues as Anticancer Agents: Synthesis and in Cell Pharmacological Studies
Anti-Cancer Agents in Medicinal Chemistry Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Meet Our Editorial Board Member:
Recent Patents on Anti-Infective Drug Discovery Polyphenols in Food: Cancer Prevention and Apoptosis Induction
Current Medicinal Chemistry